Catalog No.
DHB91702
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Beta-nerve growth factor, NGFB, Beta-NGF, NGF
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01138
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
REGN475, SAR164877, CAS: 1190239-42-9
Clone ID
Fasinumab
A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee, PMID: 25527221
A tale of two TrkA inhibitor trials: same target, divergent results, PMID: 31356877
Antibodies to watch in 2016, PMID: 26651519
Antibodies to watch in 2017, PMID: 27960628
Antibodies to watch in 2018, PMID: 29300693
Antibodies to watch in 2021, PMID: 33459118
Anti-nerve growth factor antibodies for the treatment of low back pain, PMID: 32436473
Anti-nerve growth factor in pain management: current evidence, PMID: 27354823
Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain, PMID: 28967370
Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues, PMID: 29415946
Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial, PMID: 33199274
Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee, PMID: 24686255
Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study, PMID: 25210473
Fasinumab effective for chronic low back pain, PMID: 33268836
Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?, PMID: 28660479
Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?, PMID: 28119540
Painful neurotrophins and their role in visceral pain, PMID: 29543647
Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?, PMID: 24691709
Targeting nerve growth factor to relieve pain from osteoarthritis: What can we expect?, PMID: 30266445
Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs, PMID: 33293475
The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial, PMID: 31207169
What is new in pain modification in osteoarthritis?, PMID: 29361112
For research use only. Not for human or drug use.
